Coronary Atherosclerosis: Clinical Trials

10 trials for Coronary Atherosclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 2 unknown, 1 not yet recruiting, 1 withdrawn. 10 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 310Completed 6, Unknown 2, Not yet recruiting 1, Withdrawn 1

Follow Coronary Atherosclerosis: new trials by email Literature Review of Coronary Atherosclerosis trials Research Report on Coronary Atherosclerosis

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events
Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia
Phase 3Not yet recruitingDaiichi Sankyo1032026-09-302026-09-29
Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis?
Omega 3 - Coronary Atherosclerosis
Phase 3UnknownUniversity Hospital, Clermont-Ferrand302011-03-012012-10-03
AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis
Placebo, TriLipix - Coronary Atherosclerosis
Phase 3WithdrawnPiedmont Healthcare2009-11-012024-12-18
Firefighter Aged Garlic Extract Investigation With CoQ10 as a Treatment for Heart Disease (FAITH)
Aged garlic extract and Coenzyme Q10 - Coronary Atherosclerosis, Coronary Artery Calcification
Phase 3CompletedLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center652009-05-012015-03-12
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
Placebo, Aliskiren - Coronary Artery Disease (CAD), Coronary Atherosclerosis
Phase 3CompletedNovartis Pharmaceuticals6132009-03-012014-06-03
PIoglitazone for PrEvention of Restenosis in Diabetic Patients
Pioglitazone, Placebo - Coronary Atherosclerosis, Coronary Restenosis
Phase 3UnknownUniversity of Rome Tor Vergata1602008-07-012008-08-01
CRESTOR Athero Imaging Head to Head IVUS Study
Rosuvastatin, Atorvastatin - Coronary Atherosclerosis
Phase 3CompletedAstraZeneca23332008-01-012012-07-16
Everolimus Stent in Patients With Coronary Artery Disease (CAD)
coronary stent, stent - Coronary Artery Disease, Coronary Atherosclerosis
Phase 3CompletedSan Giuseppe Moscati Hospital6002007-03-012010-08-17
STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)
Rimonabant (SR141716), Placebo - Coronary Atherosclerosis
Phase 3CompletedSanofi8392005-01-012009-04-20
Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic
Counseling, Interactive Education, Group Support - Diabetes, Dyslipidemia
Phase 3CompletedProvidence VA Medical Center2002003-07-012014-04-16

Narrower conditions

Coronary Artery Disease (10)  ·  Diabetes Mellitus (2)  ·  Coronary Restenosis (1)  ·  Coronary Stenosis (1)  ·  Diabetes Mellitus, Type 2 (1)  ·  Dyslipidemias (1)  ·  Hypercholesterolemia (1)  ·  Hypertension (1)

Broader conditions

Arterial Occlusive Diseases (10)  ·  Arteriosclerosis (10)  ·  Cardiovascular Diseases (10)  ·  Coronary Disease (10)  ·  Heart Diseases (10)  ·  Myocardial Ischemia (10)  ·  Vascular Diseases (10)  ·  Metabolic Diseases (3)  ·  Nutritional and Metabolic Diseases (3)  ·  Endocrine System Diseases (2)  ·  Glucose Metabolism Disorders (2)  ·  Lipid Metabolism Disorders (2)  ·  Coronary Stenosis (1)  ·  Dyslipidemias (1)  ·  Hyperlipidemias (1)

Interventions

Atorvastatin (2)  ·  Rosuvastatin Calcium (2)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1)  ·  Counseling (1)  ·  Docosahexaenoic Acids (1)  ·  Ezetimibe (1)  ·  Fenofibrate (1)  ·  Pioglitazone (1)  ·  Rimonabant (1)  ·  Self-Help Groups (1)  ·  Stents (1)  ·  aliskiren (1)  ·  coenzyme Q10 (1)

Sponsors

AstraZeneca (1)  ·  Daiichi Sankyo (1)  ·  Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1)  ·  Novartis Pharmaceuticals (1)  ·  Piedmont Healthcare (1)  ·  Providence VA Medical Center (1)  ·  San Giuseppe Moscati Hospital (1)  ·  Sanofi (1)  ·  University Hospital, Clermont-Ferrand (1)  ·  University of Rome Tor Vergata (1)

Countries

Italy (6)  ·  United States (6)  ·  France (4)  ·  Spain (4)  ·  Australia (3)  ·  Belgium (3)  ·  Canada (3)  ·  Poland (3)  ·  Argentina (2)  ·  Germany (2)  ·  Hungary (2)  ·  Netherlands (2)  ·  Brazil (1)  ·  Mexico (1)  ·  Russia (1)

Top investigators

Francesco Romeo, MD (1)  ·  Joseph Miller, MD (1)  ·  Matthew J Budoff, MD (1)  ·  Stephen J Nicholls, MBBS, PhD (1)  ·  Wen-Chih Wu, MD (1)

Results publications

PMID 18387931, PMID 19262209, PMID 22085316, PMID 23999933, PMID 24043299, PMID 24448227, PMID 25240453, PMID 26523993

NIH funding

2008 (1), 2025 (1)